Bonk (NASDAQ:BNKK – Get Free Report) was downgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a report released on Sunday.
Separately, Weiss Ratings lowered shares of Bonk from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, April 29th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock has an average rating of “Sell”.
Check Out Our Latest Stock Analysis on Bonk
Bonk Stock Performance
Bonk (NASDAQ:BNKK – Get Free Report) last released its quarterly earnings data on Wednesday, May 13th. The company reported ($0.23) earnings per share for the quarter. Bonk had a negative return on equity of 148.62% and a negative net margin of 838.37%.The business had revenue of $0.79 million during the quarter.
Insider Buying and Selling
In other Bonk news, Director Mitchell Austin Rudy acquired 31,055 shares of the company’s stock in a transaction on Thursday, April 9th. The shares were bought at an average cost of $2.82 per share, with a total value of $87,575.10. Following the completion of the acquisition, the director owned 44,198 shares in the company, valued at approximately $124,638.36. This trade represents a 236.29% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders own 51.60% of the company’s stock.
Institutional Inflows and Outflows
Several large investors have recently made changes to their positions in the business. State Street Corp acquired a new stake in Bonk in the 4th quarter valued at $33,000. Steward Partners Investment Advisory LLC purchased a new stake in Bonk in the 4th quarter worth $37,000. Jane Street Group LLC purchased a new stake in Bonk in the 4th quarter worth $96,000. Finally, Geode Capital Management LLC acquired a new position in Bonk during the fourth quarter worth $128,000. 12.55% of the stock is owned by institutional investors and hedge funds.
Bonk Company Profile
Safety Shot, Inc, a wellness and functional beverage company, engages in the research and development of over-the-counter products and intellectual property. Its products pipeline includes Photocil to address psoriasis and vitiligo; JW-700 to treat hair loss; JW-500 for women’s sexual wellness; NoStingz, a jellyfish sting prevention sunscreen; and JW-110 for the treatment of atopic dermatitis/eczema. The company primarily sell its products through third-party physical retail stores and partners. The company was formerly known as Jupiter Wellness, Inc and changed its name to Safety Shot, Inc in September 2023.
Recommended Stories
- Five stocks we like better than Bonk
- 3 Retail Winners Using Cash Flow to Stay Ahead
- 3 Tech ETFs That Could Bounce Back After the AI Selloff
- 3 Penny Stocks Under $5 Backed by Real Revenue Growth
- 3 Non-Pharma Firms That Could Benefit From the GLP-1 Trend
Receive News & Ratings for Bonk Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bonk and related companies with MarketBeat.com's FREE daily email newsletter.
